Home › Products › Oncology › Certican 0.75mg Tablet
Certican 0.75mg Tablet
Salt Composition: EVEROLIMUS
- Manufacturer: NOVARTIS INDIA LTD
- Pack Size: 10 TABLET(s) IN A STRIP
- Dosage Form: TABLET
- Strength: 0.75MG
- Prescription Required
- Storage: Store Certican 0.75mg tablet in the original package at room temperature (20°C to 25°C). Keep it out of reach from children.
₹2499.00₹2876.00
Inclusive of all taxes
Product Introduction
Certican 0.75mg Tablet is an antineoplastic and immunosuppressive medicine containing Everolimus as its active ingredient. It belongs to the class of mTOR kinase inhibitors, which work by blocking specific proteins that help cancer cells grow and multiply. Certican 0.75mg Tablet is used in several medical conditions including advanced breast cancer, renal cell carcinoma, pancreatic neuroendocrine tumours, and subependymal giant cell astrocytoma. In organ transplantation, this medicine plays a role in preventing the body from rejecting a transplanted kidney. Doctors prescribe it for kidney transplant patients. The Certican 0.75mg dosage for kidney transplant is determined based on patient weight, immune response, and other medications being used. Regular monitoring of blood levels helps doctors adjust the dose for safe and effective therapy. In oncology, Certican 0.75mg is used to treat patients with advanced hormone receptor-positive breast cancer, particularly those who no longer respond to other treatments. It works by slowing tumour cell growth and reducing the blood supply that tumours require to survive. When taken as prescribed, it helps improve disease control and overall quality of life. For patients considering treatment costs, Certican 0.75mg price in India varies depending on brand, pharmacy, and location. Patients can buy Certican 0.75mg online in India from licensed pharmacy websites with a valid prescription. Purchasing online ensures authenticity and timely delivery from verified distributors. If Certican 0.75mg is unavailable or if cost is a concern, a doctor may suggest a Certican 0.75mg substitute India containing the same active ingredient, Everolimus. Any substitution should be done only under medical supervision to ensure similar safety and efficacy. Certican 0.75mg Tablet is an important treatment option for both cancer and transplant patients. Its ability to regulate cell growth and control immune response makes it a recognised choice in clinical practice. Patients should take the medicine exactly as prescribed and attend regular follow-ups for optimal treatment outcomes.
Uses
Certican 0.75mg Tablet uses Advanced breast cancer Advanced renal cell carcinoma Advanced pancreatic neuroendocrine tumours Treatment of subependymal giant cell astrocytoma
How it works
Certican 0.75mg tablet inhibits the activity of a protein called mammalian target of rapamycin (mTOR), which regulates cell growth. This drug can slow the growth of abnormal cancer cells by blocking the mTOR protein and helps to reduce the size of tumours and improve outcomes in patients.
How to Use
Take the Evermil 5mg tablet as advised by your physician. Do not crush, chew, or open the medicine. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition. Only stop taking the tablet if your doctor advises you to stop.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Certican 0.75mg side effects are Serious Difficulty breathing, or swallowing Swelling of face, lips, tongue, throat Severe itching, red rash, raised bumps Common Infection (chills, increased temperature) Coughing Wheezing Excessive thirst High urine output or severely decreased urine output Tiredness Bleeding Increased appetite with weight loss
Expert Tips
Risk to unborn fetus: Certican 0.75mg tablet may cause harm to an unborn baby. Inform your doctor if pregnant: Tell your healthcare provider if you are pregnant or planning to become pregnant before starting this treatment. Pregnancy test required: Your doctor will conduct a pregnancy test before initiating treatment. Use effective contraception: Discuss birth control methods with your healthcare provider and use them during treatment and for 8 weeks after your last dose. Not recommended during breastfeeding: This medicine passes into breast milk, so breastfeeding is not advised during treatment. Mouth ulcers or sores: Mouth ulcers or sores are common; your doctor will prescribe a mouthwash to help prevent and manage these symptoms. Follow mouthwash instructions: Use the prescribed mouthwash as directed by your healthcare provider.
References
- Novartis Pharmaceuticals UK Limited, Electronic medicines compendium (EMC), [ Revised on June 2022] [ Accessed on 18th March 2023], https://www.medicines.org.uk/emc/files/pil.6658.pdf
- Jan Hasskarl; Everolimus; Recent Results in Cancer Research; Published on 2018; Accessed on 18/03/2023; https://pubmed.ncbi.nlm.nih.gov/30069763/
- Novartis Pharmaceuticals Corporation, US Food and Drug Administration, [ Revised on July 2012] [ Accessed on 18th March 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s016lbl.pdf
- Goodman & Gilmanâs, The Pharmacological Basis of Therapeutics, Targeted therapy: tyrosine kinase inhibitors, monoclonal antibodies, and cytokines, 12th edition, 2011, 1743.
- KD Tripathi, Essentials of Medical Pharmacology, Immunosuppressant drugs, 7th edition, 2013, 878 - 882.
Safety Advice
Pregnancy: unsafe Certican 0.75mg tablet is not recommended for pregnant women as it may cause fetal harm. Consult your doctor if you are pregnant or planning for pregnancy during the treatment.
Lungs: Consult your doctor It is not known whether Certican 0.75mg tablet can be used for patients with lung problems. Consult your doctor if you have any lung diseases before starting the treatment.
Breastfeeding: unsafe Certican 0.75mg tablet passes into your breast milk and harms your baby. It is unsafe to consume this tablet.
Disclaimer
The information provided on this page is intended for general informational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Self-medication can be harmful. Med For Rare does not endorse self-diagnosis or self-treatment.